A thymic peptide (marketed as Zadaxin), one of the most clinically validated immunomodulators, researched for chronic viral infections, immune restoration and as a cancer-therapy adjunct.
Approved in 35+ countries (including China, Italy, India) for chronic hepatitis B and as an immune adjuvant in immunocompromised patients — but never FDA-approved in the United States, where it is used off-label or compounded.
Also known as: Thymalfasin, Talpha1, Zadaxin
Signals through Toll-like receptors TLR2/TLR9 on dendritic cells and macrophages, maturing dendritic cells and driving CD4+ T cells toward Th1 effectors (IFN-gamma, IL-2), activating NK and cytotoxic T cells while engaging tolerogenic pathways — bidirectional immune calibration.
Its best evidence is in chronic hepatitis B, where multiple trials show delayed but sustained virological responses and improved liver histology, comparable to interferon-alpha with fewer side effects. It has also been studied in cancer-immunotherapy adjunct settings, sepsis and COVID-19 — and here honesty matters: the large, well-controlled TESTS sepsis trial (published 2025, ~1,106 patients) found no statistically significant reduction in 28-day all-cause mortality. COVID-19 evidence is mostly observational and unconfirmed by robust randomised trials. Strong hepatitis data should not be generalised to sepsis or COVID.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Generally well tolerated; reported effects are usually mild, including injection-site reactions. Its tolerability compares favourably with interferon, though long-term data outside approved indications are limited.
Interferon-alpha and antiviral or chemotherapy regimens — as an immune adjuvant. Vaccines — to boost response in immunocompromised patients, on a T-cell priming rationale.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Unlike the tissue-repair peptides here, thymosin alpha-1 is an immune modulator with genuine approvals abroad and decades of hepatitis B trial data. Its closest functional comparator is interferon-alpha, which it can match in hepatitis B with better tolerability.
No. Despite approval in 35+ countries, it is not approved in the United States.
An important limitation: a large 2025 sepsis trial showed no overall mortality benefit, and COVID evidence is largely observational. These uses are unproven.
Its evidence is in specific disease states, notably hepatitis B and immunocompromise. Benefit in healthy individuals is not established.
No reviews yet. If you've used Thymosin Alpha-1, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.